Microsoft powerpoint - istvan hernadi wg3&w4-meeting vienna 2011.10.28 [kompatibilitetsmodus]
Classification of existing co-effects and factors
University of Pecs, Faculty of Sciences, Institute of Biology,
Department of Experimental Neurobiology and Zoology
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011. Environmental factors: …ecological factor or ecofactor is any factor, abiotic or biotic, that influences living organisms (Wiki). Combined effects:
wide meaning of additivity of effects caused by two or more agents. Cooperative effects/Synergy: …synergy may be defined as two or more things (agents) functioning together to produce a result not independently obtainable (Wiki). …the interaction of elements that when combined produce a total effect that is greater than the sum of the individual elements, contributions, etc. (dictionary.com)
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011. Search Terms
Web of Knowledge (WOK), PubMed, EMF portal,
co-exposure, chemical agent, combined effects,
Number of hits dealing with EMF/RF & one of co-terms (closed on 01.06.2011)
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Most of the studies address genotoxicity (74%) and half use invitro (60%) approach.
Combined effects are reported in 70 % of the studies.
No human (in vivo) studies exist on synergistic/combinedeffects btw. EMFs and chemicals/other types of exposure.
Repetition studies (in animals) should be conducted wherepositive findings have been reported.
Human provocation studies, should be conducted, if possible,after relevant issues are identified.
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Main human-relevant in vitro co-exp. results
Endpoint: cellular excitability – (Ca2+ - influx?) Microwave influences caffeine action on the isolated frog heart (+) Pakhomov AG, Dubovick BV, Degtyariov IG, Pronkevich AN. Bioelectromagnetics.16:250-4, 1995
Caffeine (1 mM) strongly increased heart power (rate + amplitude)915 MHz burst type EMF exposure augmented the effects of caffeine
Q: is there a relevance for CNS function? See also: Apoptotic effect of ethanol is potentiated by caffeine-induced calcium release in rat astrocytes (no EMF effect tested) Hirata H, Machado LS, Okuno CS, Brasolin A, Lopes GS, Smaili SS. Neurosci Lett. 393:136-40, 2006
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Main human-relevant in vivo co-exp. Results
Endpoint: monoaminergic neurotransmitter (in)balance Amphetamine induced locomotor activity of rats (+) Thomas JR, Maitland G, Radio Science, 1979, 14: 253-258.
dextroamphetamine dose depencently induces early locomotion
in a temporal reinforcement (DRL) schedule
combined, synergistic effects are seen with 2.45-GHz pulsed EMF,
1 mW cm−2 (2 μS pulses; 500 pulses s−1). Amphetamine induced locomotor activity of rats (+) Pesić V, Janać B, Jelenković A, Vorobyov V, Prolić Z. Behav Brain Res. 2004 Apr 2;150(1-2):223-7.
Amphetamine induced psychomotor activityELF-MF exposure (60 Hz, 6 mT, 15 min) combined effects with middle doses of AMPHEffect of EMF is based on the extent of neurotransmitter inbalance
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Main human-relevant in vivo co-exp. Results
Endpoint: blood brain barrier (BBB) permeability Microwave facilitation of domperidone antagonism of apomorphine-induced stereotypic climbing in mice (+)
R. M. Quock, F. J. Kouchich, T. K. Ishii, D. G. Lange, Bioelectromagnetics 8, 45–55, 1987.
Apomorphine (DA aginist) causes stereotypic climbing behavior the behavior is antagonized by central DA antagonist haloperidol, but not by EMF (2.45 GHz, 20 mW/cm2, CW, 10 min), or domperidone (DA agonist that poorly penetrates BBB). Systemic but not central domperidone-induced effects are increased by EMF pretreatment. Mechanism: BBB opening by EMF treatment?
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Human (provocation type) co-exposure study
Endpoint: adverse cognitive effects of ELF MF co-exposed with enviromnental noise Effects of an ELF electromagnetic field (EMF) on concentration in visual attention, perception and memory including effects of EMF sensitivity (+) Trimmel M., Schweiger E., Toxicology Letters, 96,97, 377–382, 1998
ELF MF (50 Hz, 1mT) + noise reduced attention, perception and memory rates compared with either no noise or noise exposed control groups. high difference in EMF senstivie subpopulation (no difference in non-sensitive control subgroup) Results indicate immediate reduction of cognitive performance when exposed to a 50 Hz EMF of 1 mT. These effects seemed to be modulated by the self-perception of sensitivity to EMF.
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Interaction and/or synergistic effects of EMFs may exist withgenetic/biochemical/physiologal measures in animals (11 of 13in vivo studies yielded positive results).
Repetition of initial experiments is availale only on two targets(AMPH/psychomotor effects).
synergistic/combined effects btw. EMFs and chemicals. Onestudy exists with background noise as co-exposure.
Future research (repetition studies) should be conductedwhere positive findings have been reported.
Human provocation studies, should be conducted afteridentifying human relevant co-factors (caffeine, nicotine,psychoactive agents).
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Trunk A, Stefanics G, Thuroczy G, Hernadi I, et al.
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
A novel experimental protocol has been established to test
possible synergism between EMFs and (human-relevant)neuroactive chemical agents (stimulants).
Methodology has been established for the analysis of ongoing
electrophysiological activity (on a trial-by-trial basis).
The sudy entered data collection phase.
Identification of other relevant chemical agents would be
essential to be able to generalize results (regardless ifpositive /or negative…)
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
COST Action BM7040 WG 3 (in collaboration with WG4), Vienna, 28 Oct, 2011.
Informed Consent for Oral Conscious Sedation The following is provided to inform patient, or the parent/guardian of a patient under the age of 18 years, of the choices and risks involved with having treatment under conscious sedation. This information is presented to enable them to be better informed concerning their treatment. The type of sedation administered will be determined on an in
Adult Psychiatry C L I N I C A L P S Y C H I A T R Y N E W S • N o v e m b e r 2 0 0 8 E V I D E N C E - B A S E D P S Y C H I A T R I C M E D I C I N E Many Treatments Available for Clozapine-Related Drooling The Problem on the patients’ pillows. Three patientswho is finally doing well on clozapine. failed trials of benztropine or clonidinevestigators gave lofexidine 0